Organ-sparing treatment of advanced bladder cancer: Paclitaxel as a radiosensitizer

Strahlentherapie und Onkologie

Volumn 183, Issue 4, 2007, Pages 177-183

  Müller, Arndt Christian ^a,b,g   Diestelhorst, Andrea ^a   Kuhnt, Thomas ^a   Kühn, Reinhard ^c   Fornara, Paolo ^a   Scholz, Hans Jörg ^d   Dunst, Jürgen ^a,e   Zietman, Anthony Laurence ^f  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Martha Maria Hospital Halle   (Germany)

^d Asklepios Hospital Weißenfels   (Germany)

^e UNIVERSITY OF LÜBECK   (Germany)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Bladder cancer; Bladder preservation; Chemotherapy; Radiotherapy

Indexed keywords

CISPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTECTOMY; CYSTITIS; DIARRHEA; DRUG DOSE REDUCTION; ENTERITIS; FEMALE; HUMAN; MALE; METASTASIS; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; NAUSEA; NEPHROTOXICITY; PALLIATIVE THERAPY; RADIATION DOSE; RADIATION INJURY; RECURRENT CANCER; REMISSION; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PACLITAXEL; RADIATION-SENSITIZING AGENTS; RECURRENCE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 34147175393     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-007-1651-z     Document Type: Article

References (28)

1. Baierlein SA, Distel L, Sieber R, et al. Combined effect of tumor necrosis factor-alpha and ionizing radiation on the induction of apoptosis in 5637 bladder carcinoma cells. Strahlenther Onkol 2006;182:467-72.
2. Bellmunt J, Guillem V, Paz-Ares L, et al. Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer. Eur J Cancer 2000;36:Suppl 2:17-25.
3. Chen WC, Liaw CC, Chuang CK, et al. Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer. Int J Radiat Oncol Biol Phys 2003;56:726-33.
4. Coppin CM, Gospodarowicz MK, James K, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996;14:2901-7.
5. Dunst J, Diestelhorst A, Kuhn R, et al. Organ-sparing treatment in muscle-invasive bladder cancer. Strahlenther Onkol 2005;181:632-7.
6. Dunst J, Sauer R, Schrott KM, et al. Organ-sparing treatment of advanced bladder cancer: a 10-year experience. Int J Radiat Oncol Biol Phys 1994;30:261-6.
7. Dunst J, Weigel C, Heynemann H, et al. Preliminary results of simultaneous radiochemotherapy with paclitaxel for urinary bladder cancer. Strahlenther Onkol 1999;175:Suppl 3:7-10.
8. Hannisdal E, Fossa SD, Host H. Blood tests and prognosis in bladder carcinomas treated with definitive radiotherapy. Radiother Oncol 1993;27:117-22.
9. Hussain M, Vaishampayan U, Du W, et al. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 2001;19:2527-33.
10. Hussain MH, Glass TR, Forman J, et al. Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study. J Urol 2001;165:56-60.
11. Jenkins BJ, Caulfield MJ, Fowler CG, et al. Reappraisal of the role of radical radiotherapy and salvage cystectomy in the treatment of invasive (T2/T3) bladder cancer. Br J Urol 1988;62:343-6.
12. Kugler A, Haschemi R, Zoller G, et al. In vitro investigations of new therapeutic agents on bladder tumor cell lines. Urol Res 1997;25:247-50.
13. Liebmann J, Cook JA, Fisher J, et al. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 1994;86:441-6.
14. Mameghan H, Fisher R, Mameghan J, et al. Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys 1995;31:247-54.
15. Marini P, Schmid A, Jendrossek V, et al. Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer 2005;5:5.
16. Matos T, Cufer T, Cervek J, et al. Prognostic factors in invasive bladder carcinoma treated by combined modality protocol (organ-sparing approach). Int J Radiat Oncol Biol Phys 2000;46:403-9.
17. Nichols RC Jr, Sweetser MG, Mahmood SK, et al. Radiation therapy and concomitant paclitaxel/carboplatin chemotherapy for muscle invasive transitional cell carcinoma of the bladder: a well-tolerated combination. Int J Cancer 2000;90:281-6.
18. Quilty PM, Duncan W. Primary radical radiotherapy for T3 transitional cell cancer of the bladder: an analysis of survival and control. Int J Radiat Oncol Biol Phys 1986;12:853-60.
19. Raghavan D. Progress in the chemotherapy of metastatic cancer of the urinary tract. Cancer 2003;97:2050-5.
20. Rödel C. Current status of radiation therapy and combined-modality treatment for bladder cancer. Strahlenther Onkol 2004;180:701-9.
21. Rödel C, Grabenbauer GG, Kuhn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002;20:3061-71.
22. Rubin P, Constine LS, Fajardo LF, et al. RTOG Late Effects Working Group. Overview. Late Effects of Normal Tissues (LENT) scoring system. Int J Radiat Oncol Biol Phys 1995;31:1041-2.
23. Sakata KI, Someya M, Nagakura H, et al. A clinical study of hypoxia using endogenous hypoxic markers and polarographic oxygen electrodes. Strahlenther Onkol 2006;182:511-7.
24. Shipley WU, Kaufman DS, Heney NM, et al. An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy. J Urol 1999;162:445-50.
25. Sternberg CN, Calabro F, Pizzocaro G, et al. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001;92:2993-8.
26. Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000;47:13-47.
27. Vogt HG, Martin T, Kolotas C, et al. Simultaneous paclitaxel and radiotherapy: initial clinical experience in lung cancer and other malignancies. Semin Oncol 1997;24:S12.
28. Weiss C, Rodel F, Wolf I, et al. Combined-modality treatment and organ preservation in bladder cancer. Do molecular markers predict outcome? Strahlenther Onkol 2005;181:213-22.